Codexis Inc (CDXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Codexis Inc (CDXS) has a cash flow conversion efficiency ratio of -0.200x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.70 Million) by net assets ($38.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Codexis Inc market cap and net worth for the company's overall valuation and market capitalisation.
Codexis Inc - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Codexis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Codexis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Codexis Inc ranked by their cash flow conversion efficiency. Explore CDXS cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coda Octopus Group Inc
NASDAQ:CODA
|
0.009x |
|
Century Land Joint Stock Company
VN:CRE
|
-0.019x |
|
AptaBio Therapeutics Inc
KQ:293780
|
-0.061x |
|
51Talk Online Education Group
NYSE MKT:COE
|
-0.378x |
|
Odlewnie Polskie SA
WAR:ODL
|
0.063x |
|
PYRUM INNOV.AG NA O.N.
F:PYR
|
-0.116x |
|
Keyrus SA
PA:ALKEY
|
-0.164x |
|
China Electric Manufacturing Corp
TW:1611
|
0.009x |
Annual Cash Flow Conversion Efficiency for Codexis Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of Codexis Inc from 2006 to 2024. View CDXS live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $66.93 Million | $-49.41 Million | -0.738x | -21.48% |
| 2023-12-31 | $86.61 Million | $-52.64 Million | -0.608x | -879.84% |
| 2022-12-31 | $144.80 Million | $11.28 Million | 0.078x | +189.79% |
| 2021-12-31 | $164.39 Million | $-14.27 Million | -0.087x | +10.33% |
| 2020-12-31 | $170.10 Million | $-16.46 Million | -0.097x | +18.69% |
| 2019-12-31 | $105.52 Million | $-12.56 Million | -0.119x | +52.45% |
| 2018-12-31 | $56.31 Million | $-14.09 Million | -0.250x | +29.88% |
| 2017-12-31 | $24.55 Million | $-8.76 Million | -0.357x | -152.43% |
| 2016-12-31 | $19.10 Million | $-2.70 Million | -0.141x | -647.25% |
| 2015-12-31 | $22.88 Million | $-433.00K | -0.019x | -255.13% |
| 2014-12-31 | $26.31 Million | $321.00K | 0.012x | +102.20% |
| 2013-12-31 | $41.48 Million | $-23.00 Million | -0.554x | -265.68% |
| 2012-12-31 | $78.44 Million | $-11.89 Million | -0.152x | -3077.24% |
| 2011-12-31 | $102.69 Million | $-490.00K | -0.005x | +96.87% |
| 2010-12-31 | $107.36 Million | $-16.38 Million | -0.153x | +35.29% |
| 2009-12-31 | $36.84 Million | $-8.69 Million | -0.236x | -183.84% |
| 2008-12-31 | $-129.12 Million | $-36.32 Million | 0.281x | +280.22% |
| 2007-12-31 | $-87.47 Million | $-6.47 Million | 0.074x | -70.62% |
| 2006-12-31 | $-52.77 Million | $-13.29 Million | 0.252x | -- |
About Codexis Inc
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the … Read more